Healthcare Professionals

About CA125 + HE4

Know the right treatment path.

The path to optimal
patient outcomes begins
with CA125 + HE4.

The new CA125 + HE4 risk stratification tool is a new differential diagnostic for women presenting with pelvic mass to help determine the most appropriate course of care.

In a recent study, researchers found the combination of CA125 and HE4 tests could lead to earlier detection of ovarian cancer in women with pelvic mass.

In this study, 9 potential biomarkers were evaluated in 233 patients with pelvic mass. Researchers measured the levels of each biomarker in the women’s blood and then compared the results with the biopsies of their tumors. With 72.9% sensitivity and 95% specificity, HE4 was the most effective biomarker for detecting ovarian cancer. When CA125 was added, the result was an even more powerful combination of tests, with sensitivity for detecting the disease increased to 76.4%. The study also found HE4 to be the best single marker for Stage I disease.9

The CA125 + HE4 test combination is therefore designed to measure levels of each of these biomarkers in the blood to aid in the risk stratification of women who present with pelvic mass. Risk stratification helps ensure optimal patient care by promoting the triage of patients at high risk of ovarian malignancy to tertiary care centers with multidisciplinary teams that specialize in ovarian cancer.9

In summary, the CA125 + HE4 combination accurately determines risk of malignancy:9

  • Many markers have been studied, but the CA125 + HE4 combination has proven to be a more accurate predictor of malignant disease than either marker alone9
  • Patients classified as being at increased risk for ovarian cancer can be referred to a gynecologic oncologist (GYN/ONC) for
    optimal care2
  • In a prospective multi-center study, the combination assay yielded a sensitivity of 89%, with a fixed specificity of 75%23

OBG Management LogoRead "In women who have a pelvic mass
Have you tried this new ovarian Ca biomarker?"

recently published in OBG Management.

Optimal Management of Ovarian Cancer

Gynecologic oncologists are best trained for complete management of ovarian cancer. A study published in the Journal of Clinical Oncology found the percentage of pelvic mass patients who received comprehensive surgical evaluations varied significantly by the specialty of their physician3

Percent of Pelvic Mass Patients Who Received Comprehensive Surgical Evaluations per Specialty

Studies have also shown patients treated by a GYN/ONC are more likely to undergo complete surgical staging or have an optimal cytoreductive surgery, compared with patients treated by surgeons unfamiliar with the management of ovarian cancer. More importantly, recent studies have demonstrated ovarian cancer patients managed at institutions with multidisciplinary teams, and by surgeons who specialize in ovarian cancer, have fewer complications and better survival rates.2,10

Cost of Comprehensive Care per Patient Quality-adjusted Live Years

The majority of women who undergo surgery for an ovarian cyst or pelvic mass are treated in a community hospital by a gynecologist or general surgeon. Although this is appropriate for most patients, those with a malignancy should be referred to a tertiary care center with multidisciplinary teams specializing in ovarian cancer.2


See more videos in the Media Library